IgG Antibodies to GlcNAcβ and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment

Table 8

Share of patients exhibiting the AG Ab level change after Peg-IFN/RBV therapy.

Ab level in patients, %	Adi	GlcNAcβ	GA2	Bdi	GalNAcβ	PFdi	Gb5tri
Increased	45	36	30	46	21	50	8
Decreased	5	9	13	8	0	5	33
Weak or no effect	50	55	57	46	79	45	59
Increased in F0–1	45	42	47	57	25	58	20
Increased in F2–4	44	27	8	33	17	40	3